Retatrutide Plateau
Retatrutide is an investigational medication in clinical trials. It is not FDA-approved, is not legally compoundable, and is not available through Trimi. Trimi does not offer it and has no plans to. This article is editorial safety coverage for people researching the drug-development pipeline.
According to the 2023 NEJM phase 2 trial (Jastreboff et al.), retatrutide produced a mean weight reduction of up to 24.2% at 48 weeks at the highest dose, and the authors noted that weight reduction at the higher doses had not yet leveled off when the trial ended.
This article is general information, not medical advice. Weight loss results vary from person to person, and trial averages do not predict any individual outcome. Consult a licensed clinician about any medication decision, including what to do when weight loss stalls.
Related Reading
Sources & References
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. NEJM 2023. pubmed.ncbi.nlm.nih.gov/37366315
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM 2021. pubmed.ncbi.nlm.nih.gov/33567185
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022. pubmed.ncbi.nlm.nih.gov/35658024
- Fothergill E et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity 2016. pubmed.ncbi.nlm.nih.gov/27136388
- U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. fda.gov: unapproved GLP-1 drugs
- ClinicalTrials.gov, U.S. National Library of Medicine. clinicaltrials.gov